28 pages. "When considering future prescription drug policy options, it is vital to consider the implications of PBM incentive structures for patients and other stakeholders within the market: [1] PBMs benefit directly from prescription medicine list price growth, leading to misaligned incentives in the system.... [2] Excess complexity and information asymmetry in the market prevent payers and patients from properly evaluating PBM decisions or drug costs.... [3] Lack of meaningful PBM industry standards, limited transparency, and lack of regulatory oversight enable PBM revenue growth."